In this review, the pro-and anti-arrhythmic effects of a diet rich in fish oil fatty acids and of hypercholesterolemia will be discussed in relation to two major mechanisms of arrhythmogenesis (triggered activity and re-entry). Whereas a diet rich in fish oil is pro-arrhythmic in relation to re-entry based arrhythmias (as occur in acute myocardial ischemia) and anti-arrhythmic in relation to triggered activity based arrhythmias (as occur in heart failure), the reverse is true for hypercholesterolemia. Changing the lipid composition of cardiomyocytes likely has powerful pro-or anti-arrhythmic consequences, depending on the mechanism of arrhythmias, and has corresponding therapeutic potential.
Introduction
Sudden cardiac death constitutes a large medical and societal challenge, especially in the Western world (Zipes & Wellens, 1998) . Its causes are multiple and include ventricular fibrillation (VF) in patients with acute myocardial ischemia, ventricular tachycardia (VT) in patient with myocardial infarction (MI) (Janse & Wit, 1989) , VT developing into VF in patients with heart failure (Kjekshus, 1990) , and VT/VF in patients with channelopathies like the long QT syndromes (Mizusawa, Horie, & Wilde, 2014) . Rare disease like Brugada Syndrome and J-wave syndromes are also associated with VF (Brugada & Brugada, 1992; Hoogendijk et al., 2010; Miyazaki, Shah, & Haissaguerre, 2010) . The mechanisms of these arrhythmias are largely different and therefore the arrhythmias have different vulnerable factors to target for treatment or prevention (Working group on arrhythmias of the European society of cardiology, 1991). It is therefore not surprising that pharmacological prevention of life-threatening arrhythmias is unsuccessful and in some cases harmful. The CAST study has marked a turn in the development of novel anti-arrhythmic drugs because it explained the antagonistic effects of some antiarrhythmic drug (CAST, 1989) . Indeed, a compound may be anti-arrhythmic in the setting of heart failure, but may prove to be pro-arrhythmic in the setting of acute myocardial ischemia and vice versa. When developing novel anti-arrhythmic drugs and novel
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In the following I will briefly discuss some (but not all) mechanisms underlying life-threatening arrhythmias and how they are related to common arrhythmia syndromes. Furthermore, I will discuss how the electrophysiological effects of the membrane content of fatty acids or cholesterol can act as a target for anti-arrhythmic therapy. The data will show that these novel interventions do not differ from pharmacological anti-arrhythmic therapy in the sense that their efficacy is equally dependent on the type of arrhythmias studied, and that they may be pro-arrhythmic in some conditions and anti-arrhythmic in other. In some highly selected patient groups, however, in which the mechanism of the threatening arrhythmia is known or can be anticipated, dietary interventions may be used as anti-arrhythmic therapy. With the advent of non-invasive activation and repolarization mapping techniques (Zhang et al., 2015) the early definition of arrhythmia mechanisms and the localization of the arrhythmia origin is becoming feasible, thus guiding mechanism specific, patient tailored therapy that includes dietary anti-arrhythmic therapy. A comprehensive review by Billman on the effects of omega-3 polyunsaturated fatty acids, with specific focus on epidemiological studies, on the effects on heart rate and on atrial and ventricular fibrillation has appeared earlier .
Mechanisms of arrhythmias
Many reviews have been published on arrhythmia mechanisms (Coronel et al., 2013; Janse & Wit, 1989; Janse et al., 2001 ) and I will only touch on some of the major mechanisms, re-entry and triggered activity. Arrhythmias are traditionally classified as those caused by abnormal impulse generation and those with abnormal impulse propagation. This classification system is of limited value because arrhythmias are often initiated ('triggered') by abnormal impulse generation and then maintained by abnormal impulse propagation. The abnormalities may have been present before the advent of the arrhythmia and then constitute the 'substrate'. Pharmacologic (or non-pharmacologic) interventions aimed at either or both the trigger and the substrate can abolish or prevent the arrhythmia.
Re-entry (ischemia induced VT/VF)
The majority of the ventricular arrhythmias are caused by re-entrant mechanisms ('abnormal impulse propagation') (Janse, 1986) . Re-entry is defined as an activation sequence caused by a single wavefront that re-excites the site of origin. The work of Mines has laid the basis of our understanding of re-entrant arrhythmias, and already anticipated that re-entry could be of clinical importance (Mines, 1913 (Mines, , 1914 . The proof that re-entry plays a role in clinical arrhythmias came only later when the arrhythmias associated with the Wolff-Parkinson-White (WPW) syndrome was attributed to re-entry (or circus movement tachycardia) (Boukens & Janse, 2013) . Janse et al. have demonstrated that ischemia-associated arrhythmias also were caused by re-entry (Janse et al., 1980) .
For the initiation of re-entry an intricate interaction between the wavefront (the activation wave) and the wave tail (the repolarization wave) is required (Samie & Jalife, 2001) . Conduction velocity may be slowed (as in myocardial ischemia) and may facilitate that the activation wave coincides with the end of repolarization in another region of the heart. A shortening of repolarization (as occurs in myocardial ischemia) thus may facilitate this (Janse, Capucci, Coronel, & Fabius, 1985) . It will lead to a premature activation. Secondly, in the presence of heterogeneity of repolarization (Janse et al., 1985) , a closely coupled premature activation originating from the area with the early repolarization may encounter block ('unidirectional block') that will force the premature activation wave to circumvent the area of block. If the site of origin has recovered from inactivation of the sodium channel at the appropriate time (f.e. facilitated by a steep restitution slope), the premature activation front may re-enter into the area of origin (Child et al., 2015; Coronel, Wilms-Schopman, & Janse, 2011; Coronel, Wilms-Schopman, Opthof, & Janse, 2009 ).
The relation between the conduction velocity and the refractory period has been laid down in the concept of wavelength that is the mathematical product of the two (Smeets, Allessie, Lammers, Bonke, & Hollen, 1986 ). The wavelength is the theoretical path length. If a circle with a circumference of the wavelength fits in the myocardium, reentry is possible. The shorter the wavelength, the more easy it is to induce re-entry. It follows that slow conduction velocity and/or a short refractory period facilitate the onset of re-entrant arrhythmias. The concept is only theoretical, because the conduction velocity decreases when the activation wave encroaches on the tail of the wave, and restitution characteristics dynamically alter the action potential duration (or the refractory period). Finally, in some forms of re-entry (anatomical reentry, whereby the activation path is determined by a pre-existing anatomic circular path of myocardium (e.g in WPW-syndrome and tachycardia during myocardial infarction), an excitable gap is part of the wavelength.
High resolution mapping of activation and repolarization has led to a more accurate mathematical description of re-entry in the form of rotors or re-entrant drivers (Chen, Mandapati, Berenfeld, Skanes, & Jalife, 2000) . In particular, wave front-wave tail interactions follow a pattern that is determined by wave front curvature around the vortex (singularity point) of the rotor (Pandit & Jalife, 2013) . During sustained arrhythmias these singularity points move three dimensionally in the myocardium, although they tend to anchor at sites of structural or functional heterogeneities (Pandit & Jalife, 2013) .
A classical anti-arrhythmic strategy for the prevention or termination of a re-entrant arrhythmia is to prolong action potential duration with class 3 anti-arrhythmic drugs (Camm et al., 1993 ). This will both hamper initiation and maintenance of the arrhythmia.
Triggered activity (heart failure induced VT/VF)
Whereas re-entrant arrhythmias require heterogeneities occurring in a multicellular setting, triggered activity is a primarily cellular mechanism. Two types of triggered activity (TA) are distinguished: those caused by early after depolarizations (occurring during the repolarization phase of the action potential, Fig. 1A ) and those caused by delayed after depolarization (occurring following completion of the repolarization phase of the action potential, Fig. 1B ). The after depolarizations may reach the threshold level for (re)activation and thus lead to a (triggered) action potential.
Early after depolarizations (EADs) typically occur when the action potential plateau is prolonged. The latter can be detected on the ECG by a prolongation of the QT-interval. The resulting long QT-syndrome can be either acquired or have a genetic origin. Several groups of drugs that inhibit one of the repolarizing ion channels (some as a side effect) are associated with a QT-prolongation and with ventricular arrhythmias based on triggered activity.(see websites mentioned in (Postema et al., 2013 )) The genetic LQT syndromes are multiple and are each associated with mutation in one of the ion channels (or their subunits) responsible for repolarization. A characteristic tachycardia related to triggered activity by early after depolarizations is a specific subtype of polymorphic ventricular tachycardia that shows beat by beat changes in the QRS morphology, giving the impression of the QRS-complexes 'turning around the baseline'. These 'Torsade de Pointes' arrhythmias may terminate spontaneously, or develop into ventricular fibrillation. In heart failure, the action potential duration (and the QT interval) is typically prolonged, and arrhythmias are thought to be caused by triggered 'focal' activity (Janse et al., 2001; Pogwizd, 1994 Pogwizd, , 1995 Pogwizd, Schlotthauer, Li, Yuan, & Bers, 2001; Vermeulen et al., 1994; Wiegerinck et al., 2008) .
In healthy myocardium the myocytes are coupled through gap junctions that allow the exchange of matter and current between adjacent cells. As a result, transmembrane potential changes in a single cell are likely to be mitigated by the 'smoothing' effects of intercellular coupling. Whether an EAD is able to lead to a propagated action potential in whole tissue is determined by the number of cells that are simultaneously developing the triggered activity and by the degree of electrical intercellular coupling (Xie, Sato, Garfinkel, Qu, & Weiss, 2010) .
A logical strategy to counteract triggered activity based on EADs would be to shorten the action potential duration. Anti-arrhythmic drugs are not clinically available for this purpose.
Delayed after depolarization (DADs) are caused by pathologic alteration in the calcium handling mechanisms of the cell. These conditions typically occur in digitalis toxicity, heart failure, and in the delayed phase of arrhythmogenesis of acute myocardial ischemia (the 1b phase of arrhythmias). Spontaneous release of calcium from the sarcoplasmatic reticulum leads to a temporary increase in cytoplasmatic calcium concentration (Pogwizd & Bers, 2002 ). The subsequent extrusion of the calcium through the sodium/calcium exchanger then causes a depolarization of the cell membrane. Spontaneous release of calcium is secondary to an increased diastolic cytoplasmatic calcium concentration that in turn is likely caused by increased cytoplasmatic sodium (Baartscheer, Schumacher, Belterman, Coronel, & Fiolet, 2003a , 2003b Baartscheer, Schumacher, & Fiolet, 1998; Pogwizd & Bers, 2002) . Whether 1b arrhythmias are caused by delayed after depolarizations is a matter of debate, because the premature beats originate from the normal side of the ischemic border (Coronel, Wilms-Schopman, & de Groot, 2002) .
Drugs that directly reduce intracellular sodium are not yet clinically available. Cariporide, an inhibitor of the sodium/proton exchanger has been shown to be effective in reducing intracellular calcium concentration, in inhibiting the progression of heart failure and in reducing mortality in experimental animal studies, but a clinical trial has demonstrated serious side effects (Baartscheer et al., 2005; Mentzer et al., 2008) . A new antidiabetic drug, Empagliflozin reduces mortality and hospital admissions for heart failure in patients with type-2 diabetes (Fitchett et al., 2016) . The effect could not easily be attributed to the glucose-lowering effects of the drug. However, Empagliflozin demonstrates a direct cardiac effects by lowering myocardial cytoplasmatic ] through impairment of myocardial sodium/proton exchanger, (Baartscheer et al., 2016) The above demonstrates that interventions aimed at increasing or reducing the action potential duration may be pro-arrhythmic or antiarrhythmic depending on the mechanism of the arrhythmia that is being targeted (CAST, 1989; ). Thus, action potential prolongation is anti-arrhythmic for re-entrant arrhythmias but pro-arrhythmic for arrhythmias caused by triggered activity based on EADs and vice versa.
Dietary fatty acids
Early observational studies on the Inuit-population have led to the hypothesis that a diet rich in fish oils (omega-3-fatty acids) is associated with reduced cardiovascular death, in particular with reduced mortality from sudden, arrhythmic, death (Bang, Dyerberg, & Hjoome, 1976; Erkkila, Lehto, Pyorala, & Uusitupa, 2003; Kromhout, Bosschieter, & de Lezenne Coulander, 1985; Siscovick, Lemaitre, & Mozaffarian, 2003; Smith, Barraj, Kantor, & Sahyoun, 2009) . Subsequent interventional studies have in part confirmed the idea (Burr et al., 1989 (Burr et al., , 2003 Marchioli, Schweiger, Tavazzi, & Valagussa, 2001; Marchioli et al., 2002) and have initiated a wealth of mechanistic studies (Kang & Leaf, 1996 , 2000 Leaf, Xiao, Billman, & Voskuyl, 1999; Mclennan, 1993; Mclennan, Abeywardena, & Charnock, 1988; Xiao, Gomez, Morgan, Lederer, & Leaf, 1997; Xiao, Kang, Morgan, & Leaf, 1995; Xiao, Wright, Wang, Morgan, & Leaf, 1998; Xiao et al., 2001) , among others on an arrhythmic dog model with an old myocardial infarction, ischemia/reperfusion and exercise (Billman, Hallaq, & Leaf, 1994) . The dogs received the fish oils acutely (intravenously) and showed reduced inducibility of VF in the treated group. In a follow-up study, using the same model but now with a three month of dietary administration of fish oils the authors found that chronic omega-3 fatty acids supplementation failed to prevent arrhythmias but increased VF inducibility in animals previously shown to be resistant to this lifethreatening arrhythmia in this model (Billman, Carnes, Adamson, Vanoli, & Schwartz, 2012) . These studies thus suggested different actions of incorporated and circulating fatty acids, but also to a proarrhythmic effect of dietary fish-oil supplementation. The same group published studies indicating that dietary n-3 PUFA increase spontaneous calcium release and after transients in cardiac myocytes obtained from the hearts of the omega-3 PUFA treated animals (Belevych et al., 2013) . Recent large scale interventional studies in patients with an implanted cardioverter defibrillator (ICD) have not confirmed the idea that fish oils confer a protective effect against cardiovascular mortality and arrhythmias (Brouwer et al., 2006; Jenkins et al., 2008; Raitt et al., 2005) . Other trials have studied the effect of fish-oils in cardiovascular mortality. For example, in the OMEGA trial fish oil supplementation was studied on top of standard MI-therapy, and no effect on sudden cardiac death was documented in the fish oil group (Rauch et al., 2010) . The Alpha Omega trial was aimed at a secondary prevention population of patients and did not document an effect of fish oils on major cardiovascular events (Kromhout, Giltay, Geleijnse, & Alpha Omega Trial, 2010) . However, a secondary analysis of the data with emphasis on ventricular arrhythmias revealed a reduction in arrhythmias in the fish oil groups (Kromhout et al., 2011) . The ORIGIN, SU.FOL.OM3 and the RISK & PREVENTION trials all did not show a reuction in major cardiovascular events (including death) in the fish oil groups (Galan et al., 2010; Investigators et al., 2012; Risk & Prevention Study Collaborative, 2013) .
Of course, the differences in outcome between these trials and between these and the earlier trials can be attributed to differences in the dosage of fish oils, whether the trials were secondary or primary prevention trial, to the duration of the follow-up, to the lack of statistical power or to the differences in standard therapy (that may have improved along the years). Nevertheless, systematic reviews have been published to address the question whether fish-oils prevent cardiovascular death or arrhythmias. Enns et al. conclude that in patients with peripheral vascular disease there was 'no evidence to suggest a protective association between omega-3 PUFA supplementation and clinical cardiovascular outcomes, including …cardiovascular death…'. (Enns et al., 2014) . Similarly, a systematic review of the results of three trials on fish oils on ventricular arrhythmias in patients with ICDs showed 'no convincing protective effect of fish oil' (Brouwer et al., 2009) .
To explain these contradictory results of the mechanistic studies on one hand and the heterogeneous epidemiological studies on the other, we hypothesized that the composition of these clinical study groups did not reflect a single but likely multiple arrhythmia mechanisms, and the failure to detect an overall effect of fish oil therapy may have been caused by a pro-arrhythmic effect in one group and a simultaneous anti-arrhythmic effect in the other , 2009 ). The first question to be answered is, therefore, what the effects of chronic fish oil feeding are in normal myocardium before testing this in models of pathology. The models of cardiac pathology are then to be selected on the basis of an established, single, mechanisms of arrhythmias rather than a combination of mechanisms as in the complex (but realistic) model of the group of Billman (Billman et al., 2012) .
Normal myocardium
We subjected pigs to a 2 months diet of omega-3 fatty acids and compared these to those that received an omega-9 fatty acids (sunflower oil) diet (with the same caloric content). Myocytes were isolated and studied under current-clamp and voltage-clamp conditions. In the fish oil group, a large reduction of the action potential duration was observed, that could be attributed to a decrease in the L-type Ca 2+ -current and Na + /Ca 2+ exchange current, and an increase in the inward rectifier K + -current and the slow delayed rectifier current compared to control . It is of interest to note that fatty acids were not included in the superfusion fluid during the electrophysiological study, and that, therefore, the observed effects must have been consequent to fatty acids incorporated into the sarcolemma. Indeed, the sarcolemma did contain increased amount of the fatty acid . This points to a potential differential effect of fish oil incorporated into the membrane versus a direct effect of circulating fish oils. However, in a subsequent study on isolated ventricular myocytes obtained from rabbits subjected to a dietary regimen similar to that described above for pigs, we established that the action potential shortening effect observed in pigs was reproduced, but that addition of circulating fish oil fatty acids did not further decrease the action potential duration in cells from fish oil fed rabbits. In control myocytes (from animals fed omega-6 fatty acids) action potential shortening following acute superfusion of fish oil fatty acids was still observed (Den Ruijter, Verkerk, & Coronel, 2010) .
The mechanism of the fish oil induced electrophysiological consequences is not entirely clear. We surmise that changes in the fluidity of the lipid bilayer plays a role in modulation of ion channel function (Leifert, Jahangiri, & McMurchie, 2000) .
Heart failure induced VT/VF (triggered activity)
Whether the changes induced by fish oil possibly explain a pro-or anti-arrhythmic action of dietary fish oils was addressed in follow-up studies. First, ventricular myocytes from healthy pigs (on a diet as described above) were subjected to a blocker of the rapid component of the delayed rectifier current . This intervention recapitulates changes also observed in heart failure where it concerns a prolongation of the action potential to a degree at which early after depolarizations and triggered activity are observed. In the myocytes from fish-oil fed pigs less action potential prolongation and less EADs were observed than in the control myocytes . Also, delayed after depolarizations, induced by rapid pacing in the presence of noradrenalin, were less seen in myocytes from the fish oil group in comparison with the sunflower oil group (Berecki et al., 2007) . In these experiments, the prolongation of the diastolic interval (consequent to a shortening of the action potential duration at the same cycle length) probably allowed improved re-uptake of Ca 2+ into the sarcoplasmatic reticulum. Acute administration of fish oil to myocytes isolated from rabbits with heart failure (created by combined volume-and pressure overload (Baartscheer et al., 2005) ) also led to a reduction in the number of delayed after depolarization and calcium-after transients induced by combined rapid pacing and noradrenalin superfusion (Den Ruijter et al., 2008) . The same observation was made in myocytes from patients with end-stage heart failure who had undergone cardiac transplantation (Den Ruijter et al., 2008) .
Combined, these data support the notion that a fish oil rich diet may prevent arrhythmias caused by triggered activity induced by early and delayed after depolarization, especially in the setting of heart failure. The effect of fish-oil is established through an alteration of the ionic currents responsible for the cardiac action potential.
Progression of heart failure
Heart failure is associated with triggered arrhythmias (Coronel et al., 2013; Janse et al., 2001) . During heart failure, the cardiac metabolic substrate preference changes from fatty acid toward glucose oxidation (van Bilsen, Smeets, Gilde, & van der Vusse, 2004) . This change may induce or advance heart failure (Dávila-Román et al., 2002) . By providing a diet rich in fish-oil fatty acids the onset of the change of metabolic substrate preference may be delayed or prevented. Thus, in addition to a direct, electrophysiological anti-arrhythmic effect on heart failure induced arrhythmias, a fish-oil rich diet may have an indirect, metabolic, anti-arrhythmic effect. This idea was tested in a model of heart failure in rabbits. The rabbits were fed either a diet rich fish-oil, sunflower oil or a control diet (Den Ruijter et al., 2012) . Heart failure was induced by volume and pressure overload (Baartscheer et al., 2005) . After 4 months, both the sunflower oil and the fish oil groups had a lower relative heart and lung weight than control, indicative of less progressed hypertrophy. Action potential duration in the fish oil group was shorter (about 20%) and triggered activity and Ca 2+ -after transients were less than in the sunflower oil group. Thus, a diet rich in unsaturated fatty acids (either fish oil or sunflower oil) initiated prior to induction of heart failure prevents the development of heart failure. Dietary fish oil in addition prevents heart failure induced electrophysiological remodeling and arrhythmias. Thus, fish oil fatty acids have a double anti-arrhythmic effect, one indirectly by postponing the development of heart failure (and its associated arrhythmias), the other directly by shortening the cardiac action potential.
Ischemia induced VT/VF (re-entry)
Acute myocardial ischemia often leads to ventricular fibrillation within minutes (Janse & Wit, 1989 ). The ischemia-induced arrhythmias are typically re-entrant and are set off by a ventricular premature activation originating from the normal myocardium and caused by the 'current of injury' (Coronel, Wilms-Schopman, Opthof, Van Capelle, & Janse, 1991; Janse et al., 1980) . Re-entrant activation during ischemia is promoted by the electrophysiological heterogeneities that occur inside the blood-deprived tissue (the 1a phase of arrhythmias), or by the process of intercellular uncoupling in a somewhat later stage of ischemia (the 1b phase of arrhythmias) (Coronel et al., 1988 (Coronel et al., , 2002 de Groot & Coronel, 2004; de Groot, Wilms-Schopman, Opthof, Remme, & Coronel, 2001; Kaplinsky, Ogawa, Blake, & Dreifus, 1979) .
Because re-entrant activation is facilitated by a shortened refractory period and action potential duration, it was anticipated that a diet rich in fish oil is associated with an increased incidence of ventricular arrhythmias during acute myocardial ischemia. This was tested in a chronic model of feeding of pigs (as mentioned above). Indeed, more arrhythmias occurred in the fish-oil group than in the control group, concurrent with a larger reduction in excitability, but unexpectedly not with a difference in refractory period . It is possible that the refractory period extended beyond the moment of repolarization (post repolarization refractoriness) (Coronel, Janse, Opthof, Wilde, & Taggart, 2012) . These data are in contrast to those by Billman et al. who demonstrated an anti-arrhythmic effect of acutely administered fish oil to a dog model of ischemia induced myocardial ischemia (superimposed on a previous myocardial infarction and following exercise) (Billman, Kang, & Leaf, 1999 ). The discrepancy is likely explained by the more moderately arrhythmogenic porcine model in comparison with the dog model (all dogs developed ventricular fibrillation), the coexistence of myocardial infarction and the acute administration of the fish oils. In a follow-up study, a pro-arrhythmic effect of fish oil has been documented in the same model, in dogs with no prior inducible ventricular fibrillation (Billman et al., 2012) .
An alternative or additional explanation for the pro-arrhythmic effect of fish oils is that the action potential shortening effect of acutely administered fish oil occurred in a heterogeneous manner (Verkerk, Den Ruijter, de Jonge, & Coronel, in press ). These heterogeneities may also facilitate the occurrence of unidirectional block and re-entry (Han & Moe, 1964; Mines, 1913) .
The observations that fish oil fatty acids my promote ventricular arrhythmias in ischemia, but reduce arrhythmias in heart failure may yield support to the results of clinical trials that showed proarrhythmia in patients with angina (ischemia related, the DART-2 trial) on one hand and a reduction in all cause mortality in patients with heart failure on the other (GISSI-HF trial) (Burr et al., 2003; Tavazzi et al., 2008) .
Cholesterol
Obese patients with high levels of cholesterol display prolongation of the QT interval (el-Gamal et al., 1995) . It is unknown whether the prolongation of the action potential is causally related to the cholesterol levels, or to the co-morbidities associated with obesity (like hypertension). A causal relation between serum cholesterol levels and action potential prolongation is suggested by the observation that cholesterol (LDL)-lowering therapy with atorvastatin slightly shortens the QT interval (Vrtovec et al., 2005) . Alternatively, increased membrane content of cholesterol leads to alterations in the structure of caveolae and the specialized cholesterol-and sphingolipid-enriched membrane microdomains, that may in turn underlie the electrophysiological changes, because ion channels have been topically associated with caveolae (Maguy, Hebert, & Nattel, 2006) .
To differentiate between these options we studied two strains of mice with a human congenital defect in cholesterol handling and compared the action potential to those in control (wild type) mice (Baartscheer et al., 2015) . Mice deficient in the LDL receptor typically display increased serum content of LDL-cholesterol, whereas the mice with absent APOA1 show decreased serum levels of HDL-cholesterol (Fig. 2) . However, cellular levels of total cholesterol were similarly increased in both mouse strains (Fig. 2) (Baartscheer et al., 2015) . In addition, both mouse strains demonstrated an equally increased QT-interval (corrected for heart rate, QTc), suggesting that the prolongation of the action potential was more likely related to the sarcolemmal cholesterol content than the circulating LDL-or HDL-cholesterol levels. Indeed, when action potentials were recorded from myocytes isolated from the hearts of these mice in the absence of circulating cholesterol, an equally prolonged action potential duration was recorded in both types of mice (Fig. 3) . The action potential prolongation was related to In the LDL−/− mice LDL serum cholesterol is increased, whereas in the ApoA1−/− mice HDL serum cholesterol is decreased compared to control (WT, wild type). B. In both mice strains, cellular cholesterol is increased, and sphingolipids are decreased. Reproduced with permission (Baartscheer et al., 2015) .
an increased L-type Ca 2+ -current in both dyscholesterolemic mouse strains compared to control, in the absence of expression differences (Baartscheer et al., 2015) .
Ischemia induced VT/VF (re-entry)
The induction of a re-entrant arrhythmia is impeded in the presence of a prolonged action potential duration (Mines, 1913) . It is therefore expected that ischemia-induced re-entrant arrhythmias occur less frequent in hypercholesterolemic mice than in wild type mice. This was tested by Baartscheer et al. who produced regional ischemia (30 min) in Langendorff perfused mouse hearts (Baartscheer et al., 2015) . Indeed, the inducibility and duration of VT/VF was significantly reduced, and the arrhythmia cycle length was significantly increased in the dyscholesterolemic mice compared to the control mice. It is of interest to note that the mouse hearts were perfused with a normal crystalline perfusion medium without cholesterol. This also points to the electrophysiologic role of incorporated membrane cholesterol rather than of the serum cholesterol.
The occurrence of re-entry reflects the combined presence of the triggering mechanisms and the substrate, whereas the occurrence of single premature beats likely only reflects the presence of the triggering mechanism (Janse et al., 1980) . The sum of all arrhythmias, therefore, represents the total number of triggers (whether or not they result in re-entry). The experiments by Baartscheer et al. show that the total number of ischemia-induced arrhythmias (single premature beats, couplets, VT and VF) was the same in wild type and dyscholesterolemic hearts. The reduction of re-entry based arrhythmias in dyscholesterolemic mice (see above), demonstrates that although the number of triggers was the same in the groups, the substrate for re-entry was less present in the dyscholesterolemic mice.
These data suggest that hypercholesterolemia, although it causes atherosclerosis and coronary artery disease (McNamara, 2000) , may be protective against ischemia induced arrhythmias. Dekker et al. have performed a case-control study of patients with a first myocardial infarction, comparing patients with and without ventricular fibrillation (Dekker et al., 2006) . A family history of sudden cardiac death (SCD) occurred more often in the VF group, and hypercholesterolemia was significantly associated with the absence of VF. The authors emphasized that 'SCD among parents and siblings is such a strong predictor of primary VF' (Dekker et al., 2006) and inferred a genetic disposition for primary VF focusing primarily on ion channel and gap junction defects. The direct electrophysiological effects of an increased sarcolemmal cholesterol may offer an alternative explanation for the observations by Dekker. The familial occurrence of (the absence of) VF may well be related to intergenerational persistence of dietary habits or to the absence of genetic dyscholesterolemia. The latter was not tested (Dekker et al., 2006) .
Heart failure induced VT/VF (Triggered activity)
Heart failure is associated with an increased action potential duration and QT-interval and with arrhythmias caused by triggered activity (based on EADs and/or DADs) (Janse et al., 2001; Pogwizd, 1994) . A shortening of action potential duration may therefore be anti-arrhythmic, as was shown by the dietary experiment on fish oils (see above). Serum cholesterol-reducing therapy may be equally effective, but this has not been established.
Den Ruijter et al. have studied patients with familial hypercholesterolemia in whom reconstituted HDL was infused (Den Ruijter et al., 2011) . The patients showed a decrease in QTc-interval in association with an increase in serum ApoA-1. Reconstituted HDL applied to cardiac myocytes from rabbits likewise reduced action potential duration (Den Ruijter et al., 2011) . (Fig. 4.) 
Conclusions
Dietary interventions that lead to changes in sarcolemmal fatty acid or cholesterol content have direct and indirect electrophysiological consequences. Increased sarcolemmal cholesterol content causes action potential prolongation, whereas increase fish oil fatty acids induce action potential shortening. These differential effects on action potential duration have implications for arrhythmogenesis. The action potential prolonging action of cholesterol will likely aggravate arrhythmias in diseases that are accompanied by a prolonged QT-interval (the long QT syndromes, heart failure), whereas the action potential shortening action of fish oil fatty acids have been shown to promote re-entry based arrhythmias.
Conversely, lipid lowering therapies will likely also counteract the pro-arrhythmic action of hypercholesterolemia in heart failure or in LQT syndrome patients. Fish oil fatty acids act anti-arrhythmic in the setting of heart failure (triggered activity based arrhythmias), whereas increased cholesterol is anti-arrhythmic in the setting of acute ischemia (re-entry based arrhythmias).
Thus, diets rich in cholesterol or fish oil fatty acids (or lipid lowering therapies) exert beneficial or contrary effects, depending on the arrhythmia mechanism . In this respect dietary interventions do not differ from pharmacological anti-arrhythmic interventions. This implies that only clinical anti-arrhythmic studies in which the patients are grouped according to arrhythmia mechanisma feature that admittedly is difficult to realize-are likely to produce unequivocal results.
Changing the lipid composition of cardiomyocytes likely has powerful pro-or anti-arrhythmic consequences, depending on the mechanism of arrhythmias, and has corresponding therapeutic potential. 
